TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease
🧪 Overview
TREM2 loss-of-function variants impair microglial survival, clustering around amyloid plaques, and phagocytic clearance, creating a non-cell-autonomous amplification loop where dysfunctional microglia accelerate tau pathology. This hypothesis has the strongest human genetic support (R47H OR ~2-4 for AD risk) and active clinical validation through AL002c Phase II trials (TRAILBLAZER-ALZ2). The mechanism is druggable via agonism antibodies, with validated biomarker (sTREM2) for patient stratification. Key uncertainties include timing dependency—TREM2 agonism likely beneficial only in early-mid disease—and species differences in TREM2 signaling. The Skeptic's revised 0.78 confidence captures the modest effect size and bidirectional complexity, while Domain Expert assigns 0.82 reflecting the clinical validation trajectory.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["TREM2 Deficiency<br/>Microglial Lipid Sensing Loss"]
B["DAM Transition Failure<br/>Failed Amyloid Phagocytosis"]
C["Amyloid Plaque<br/>Accumulation"]
D["Plaque-Associated<br/>Neurite Dystrophy"]
E["Synaptic Loss<br/>Cognitive Decline"]
F["TREM2-Deficient Microglia<br/>as Drivers of Toxicity"]
A --> B
B --> C
C --> D
D --> E
A --> F
F --> C
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TREM2
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for TREM2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF AL002c (TREM2 agonism antibody) is administered to prodromal-mild AD patients (CDR 0.5-1.0) with elevated amyloid PET for ≥18 months THEN plasma p-tau181 concentration will increase significantly m | ≥30% reduction in plasma p-tau181 annualized rate of change in AL002c-treated group vs. placebo in prodromal-mild AD | — no observation — | pending | 0.74 |
| IF TREM2 agonism enhances microglial amyloid phagocytosis in early-mid AD THEN 18F-flutemetamol PET SUVR will decline significantly faster in the AL002c arm than placebo due to reduced plaque burden, | Significantly greater reduction in cortical amyloid PET SUVR (≥0.05 units) in AL002c-treated early-mid AD patients vs. placebo after 12-18 months of treatment | — no observation — | pending | 0.68 |
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |